Backgrounds: To improve health, an increasing number of adults
are attempting to lose weight. Moreover, the number of childbearing women
targeting weight loss has increased, with a surge in pregnant women exposed to
anti-obesity drugs. This study aimed to evaluate the ingredients, types, and
trends of anti-obesity drugs and pregnancy outcomes among the exposures of
anti-obesity drugs. Additionally, we reviewed their teratogenicity in literature. Methods: We performed a prospective cohort study and recruited
pregnant women exposed to anti-obesity drugs in the Motherisk Database, from 2012
to 2018. We determined the frequency and type of anti-obesity drugs used.
Furthermore, we compared the annual change in the frequency of anti-obesity drugs
with that of total pregnancies. Overall, 30,704 pregnant women were enrolled
during the study period. Results: The rate of pregnant women exposed to anti-obesity
drugs was 4.8% (1487/30,704). The rate of pregnant women exposed to
anti-obesity drugs significantly increased from 3.7% in 2012 to 7.4% in 2018
(p
Cite this article
150
Downloads
1
Citations
367
Views
Announcements
Open Access
Original Research
Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy
Show Less
1
Department of Obstetrics and Gynecology, Inje University Ilsan Paik Hospital, Korean MotherSafe Counselling Centre, 10380 Goyang City, Korea
*Correspondence: hanjungyeol055@gmail.com (Jung Yeol Han)
Clin. Exp. Obstet. Gynecol. 2021, 48(3), 514–522;
https://doi.org/10.31083/j.ceog.2021.03.2331
Submitted: 21 October 2020 | Revised: 26 February 2021 | Accepted: 5 March 2021 | Published: 15 June 2021
(This article belongs to the Special Issue Obesity in pregnancy: risks and management)
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
Keywords
Pregnancy
Anti-obesity drugs
Teratogen
Obesity
Overweight
Figures
Fig. 1.